CGTX
USDCognition Therapeutics Inc. Common Stock
السعر في الوقت الحقيقي
مخطط الأسعار
المقاييس الرئيسية
مقاييس السوق
الافتتاح
$1.600
الأعلى
$1.630
الأدنى
$1.550
الحجم
1.39M
أساسيات الشركة
القيمة السوقية
138.5M
الصناعة
التكنولوجيا الحيوية
البلد
United States
إحصاءات التداول
متوسط الحجم
5.54M
البورصة
NCM
العملة
USD
نطاق 52 أسبوعاً
أخبار ذات صلة
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target
PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
- The offering was made to two new fundamental institutional investors - - The Company intends to use the net proceeds to fund preparation for our Phase 3 programs of zervimesine in neurodegenerative disorders -
Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, was
أسهم ذات صلة
ابق على اطلاع
تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.